Prof Ravi Salgia speaks to ecancer about the anti-tumour activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers.
Initially, he discusses the rationale of this study.
He explains that RMC-4630 is a potent, selective, orally bioavailable allosteric inhibitor of SHP2, a central node in the RAS signalling pathway.
Preclinical data have demonstrated that RMC-4630 has activity against tumours harbouring certain mutations in the RAS pathways such as KRASG12C, NF1LOF (loss of function), and BRAFClass3 (lack of/impaired kinase activity).
Prof Salgia then mentions the methodology and key results of the study.
This study showed that inhibition of pERK in patient tumours confirmed tumour intrinsic on-target activity of RMC-4630 and change of immune biomarkers in patient blood and tumours during treatment with RMC-4630 was consistent with enhancement of innate and adaptive anti-tumour immunity by RMC-4630.
In the end, Prof Salgia talks about the future of this study.